NeuroMab™ Anti-FGFR1 BBB Shuttle Antibody(NRZP-1022-ZP3894)

Figure 1. The graph shows the specificity of IMB-R1 binding to FGFR1b, FGFR1c relative to FGFR2c and FGFR3c.

Figure 2 is a graph showing that IMB-R1 specifically blocks phosphorylation of FGFR1 (stimulated by FGF2) but not FGFR2 or FGFR3.

Figure 3 Graph showing growth inhibition of osteosarcoma cells induced by IMB-R1.

Figure 4. Graph showing the effect of IMB-R1 on caspase 3 activity in MG63 cells.

Figure 5 is a graph showing the effect of IMB-R1 on the mRNA expression of p53, p21, c-Myc and Rb in MG63 cells.

Figure 6 Western blot showing the effect of FGF2 on the phosphorylation of FGFR in MG63 cells. Graph showing the effects of FGF2 and IMB-R1 on the proliferation of MG63 cells.

Figure 7 Western blot shows the effect of FGF2 on ERK phosphorylation in MG63 cells. (B) Western blot showing the effect of IMB-R1 on FGF2-induced ERK phosphorylation in MG63 cells.

Figure 8 is a graph showing the binding specificity of IMBR1. IMBR1 binds to FGFR1b and FGFR1c in a dose-dependent manner.

Figure 9 is a graph showing the effect of IMBR1 on the growth of Saos-2 cells.

Figure 10 is a graph showing the inhibitory effect of affinity purified IMB-R1 on cell growth.

Figure 11 shows a graph showing the binding of IMBR1 mAb clones to the cell surface. RnD-MAB765 and SC-57130 are commercial FGFR1 monoclonal antibodies from R&D systems and Santa Cruz, respectively.

Figure 12 shows the binding of IMBR1 mAb clones to denatured protein (MG63 total cell lysate).

Figure 13 Graph showing inhibition of cell growth by IMBR1 mAb clone.